Immunovant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential
November 28 2023 - 7:00AM
Immunovant, Inc. (Nasdaq: IMVT), a
clinical-stage immunology company dedicated to enabling normal
lives for people with autoimmune diseases, today announced initial
data from 600 mg MAD cohort of a Phase 1 clinical trial of
IMVT-1402 in healthy adults. The results show that four
subcutaneously administered doses of 600 mg produced a mean IgG
reduction similar to high dose batoclimab, but with minimal changes
in albumin and LDL-C similar to those in placebo, confirming the
potential of IMVT-1402 as a best-in-class neonatal fragment
crystallizable receptor (FcRn) inhibitor.
“We are energized by this potential best-in-class profile, which
opens the door to a unique portfolio of first-in-class and
best-in-class indications for IMVT-1402, with an emphasis on those
indications where potency matters most,” said Pete Salzmann, M.D.,
chief executive officer at Immunovant. “FcRn inhibition is a proven
mechanism with broad applicability, and we believe that a growing
body of evidence supports a consistent correlation between deeper
IgG reduction and greater efficacy. This translates to the
potential to build a class-leading anti-FcRn franchise with
IMVT-1402.”
The Phase 1 clinical trial is a randomized, double-blind,
placebo-controlled ascending dose study to assess the safety,
tolerability, pharmacokinetics, and pharmacodynamics of IMVT-1402
in healthy adults. Four once-weekly SC injections of 600 mg
IMVT-1402 reduced total IgG level by a mean of 74%, a potency that
is similar to batoclimab at 680 mg that reduced IgG by 76% after 4
weekly doses. In disease settings where batoclimab was administered
continuously, a reduction of 80% was observed at steady state after
about 6-8 weeks. We believe steady state IgG reduction with
IMVT-1402 will match this result and timing.
Across all doses evaluated, treatments with IMVT-1402 were
generally well tolerated with only mild or moderate
treatment-emergent adverse events observed. Serum albumin and LDL-C
at Day 29 (peak pharmacodynamic impact) did not show a significant
decrease or increase, respectively, from baseline (p-values >
0.05).
Conference Call & Webcast:Immunovant will
host a conference call with accompanying slides and a simultaneous
webcast today, November 28, 2023 at 8:00 a.m. EST to discuss the
600 mg multiple-ascending dose data. To participate in the
conference call, please register in advance here. To access the
live and archived webcast, please visit Immunovant’s website at
https://www.immunovant.com/investors/news-events. The archived
webcast will be available for a limited time on the Company’s
website.
About IMVT-1402IMVT-1402 is designed to be a
potentially best-in-class anti-FcRn antibody for the treatment of
IgG-mediated autoimmune diseases. In the initial results of a Phase
1 clinical trial in healthy adults, IMVT-1402 demonstrated
favorable pharmacodynamic and safety data. These attributes,
combined with a convenient route of administration that may enable
patient self-administration, position IMVT-1402 well as a potential
treatment for a variety of autoimmune diseases associated with
patient unmet need.
About Immunovant, Inc.Immunovant, Inc. is a
clinical-stage immunology company dedicated to enabling normal
lives for people with autoimmune diseases. As a trailblazer in
anti-FcRn technology, the Company is developing innovative,
targeted therapies to meet the complex and variable needs of people
with autoimmune diseases. For additional information on the
Company, please visit www.immunovant.com.
Forward-Looking StatementsThis press release
contains forward-looking statements for the purposes of the safe
harbor provisions under The Private Securities Litigation Reform
Act of 1995 and other federal securities laws. The use of words
such as "can," “may,” “might,” “will,” “would,” “should,” “expect,”
“believe,” “estimate,” “design,” “plan,” "intend," and other
similar expressions are intended to identify forward-looking
statements. Such forward looking statements include Immunovant’s
expectations regarding the timing, design, and results of clinical
trials of its product candidates; Immunovant's plan to develop
batoclimab and IMVT-1402 across a broad range of autoimmune
indications; potential benefits of batoclimab’s and IMVT-1402’s
unique product attributes; and IMVT-1402’s potential best-in-class
profile including IgG reduction and tolerability. All
forward-looking statements are based on estimates and assumptions
by Immunovant’s management that, although Immunovant believes to be
reasonable, are inherently uncertain. All forward-looking
statements are subject to risks and uncertainties that may cause
actual results to differ materially from those that Immunovant
expected. Such risks and uncertainties include, among others:
initial results or other preliminary analyses or results of early
clinical trials may not be predictive final trial results or of the
results of later clinical trials; the timing and availability of
data from clinical trials; the timing of discussions with
regulatory agencies, as well as regulatory submissions and
potential approvals; the continued development of Immunovant’s
product candidates, including the timing of the commencement of
additional clinical trials ; Immunovant’s scientific approach,
clinical trial design, indication selection, and general
development progress; future clinical trials may not confirm any
safety, potency, or other product characteristics described or
assumed in this press release; any product candidate that
Immunovant develops may not progress through clinical development
or receive required regulatory approvals within expected timelines
or at all; Immunovant’s product candidates may not be beneficial to
patients, or even if approved by regulatory authorities,
successfully commercialized; the potential impact of global
factors, such as the post-COVID-19 environment, geopolitical
tensions, and adverse macroeconomic conditions on Immunovant’s
business operations and supply chain, including its clinical
development plans and timelines; Immunovant’s business is heavily
dependent on the successful development, regulatory approval and
commercialization of batoclimab and IMVT-1402; Immunovant is at an
early stage of development for IMVT-1402 and in various stages of
clinical development for batoclimab; and Immunovant will require
additional capital to fund its operations and advance batoclimab
and IMVT-1402 through clinical development. These and other risks
and uncertainties are more fully described in Immunovant’s periodic
and other reports filed with the Securities and Exchange Commission
(SEC), including in the section titled “Risk Factors” in
Immunovant’s Form 10-Q filed with the SEC on November 9, 2023, and
Immunovant’s subsequent filings with the SEC. Any forward-looking
statement speaks only as of the date on which it was made.
Immunovant undertakes no obligation to publicly update or revise
any forward-looking statement, whether as a result of new
information, future events, or otherwise.
Contact:Chau Cheng, PhD, MBAVice President,
Investor RelationsImmunovant, Inc.info@immunovant.com
Jaye Bea SmalleyHead, Patient AdvocacyImmunovant,
Inc.mediarelations@immunovant.com
Immunovant (NASDAQ:IMVT)
Historical Stock Chart
From Apr 2024 to May 2024
Immunovant (NASDAQ:IMVT)
Historical Stock Chart
From May 2023 to May 2024